GlassScriptPhysician profile
Veronique Edward
NPI 1982264974
$5,581.37
in general payments reported to CMS, 2019-2025
19 companies · $683 in 2025
The $683 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2021: $1,207 · 2022: $2,156 · 2023: $725 · 2024: $603 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,007.95 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $559.76 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $380.87 | 2023-2025 | Infuse, Biotrue One Day, Miebo |
| Dompe US, INC. | $347.29 | 2022-2025 | Oxervate |
| Allergan, INC. | $253.99 | 2021 | |
| Alcon Vision LLC | $230.26 | 2025 | Precision7, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $224.90 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $218.84 | 2019-2021 | |
| Abbvie INC. | $189.18 | 2023-2025 | Durysta |
| Coopervision INC. | $187.85 | 2019-2025 | Clariti Contact Lens |
| Biotissue Holdings INC. | $179.51 | 2024 | |
| Rxsight INC | $139.76 | 2022-2023 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Sight Sciences, INC. | $127.88 | 2021 | |
| Horizon Therapeutics Plc | $124.97 | 2021 | |
| Amgen INC. | $121.26 | 2024 | Tepezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $109.43 | 2022 | |
| Kala Pharmaceuticals, INC. | $108.36 | 2021 | |
| Oyster Point Pharma, INC. | $55.71 | 2022-2024 | Tyrvaya |
| Omeros Corporation | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronique Edward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.